Empagliflozin on the Function of Left Atrium in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Sponsor
Zhijun Sun
Study ID
NCT05600387
Phase
PHASE4
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The number of heart failure with mildly reduced or preserved ejection fraction gradually increases. SGLT2-i has been shown to reduce the risk of hospitalization for heart failure and cardiovascular death among patients with chronic heart failure and a left ventricular ejection fraction of 40% or more . However,its effect on the function on left atrium in heart failure with mildly reduced or preserved ejection fraction is still unknown.

Key Dates

Start date
Nov 5, 2022
Status verified
Mar 2023
Primary completion
Oct 31, 2024
Completion
Oct 31, 2025

Study Design

Enrollment
100 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Empagliflozin group
    subjects in Empagliflozin group take 10mg Empagliflozin 10mg per day
  • No Intervention: Control group
    subjects in Control group will not receive Empagliflozin or other sglt-2 inhibitors

Primary Outcome Measure

change of peak atrial longitudinal strain during 6 months [ Time Frame: 6 months ]

Related Studies